CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The MABSOT project aims to develop a novel antibody, OPN-305, to prevent delayed graft function in kidney transplants. By inhibiting a specific receptor involved in tissue injury, the project seeks to improve transplant outcomes and patient quality of life.
Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy.
The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft.
Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ tran…
OPSONA THERAPEUTICS LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Lincoln
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Belgium, Leuven
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, L'Hospitalet De Llobregat
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
